Medical - Distribution
Compare Stocks
2 / 10Stock Comparison
GRDN vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
GRDN vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Distribution | Medical - Healthcare Plans |
| Market Cap | $2.32B | $111.32B |
| Revenue (TTM) | $1.46B | $407.90B |
| Net Income (TTM) | $53M | $2.93B |
| Gross Margin | 20.2% | 13.9% |
| Operating Margin | 6.4% | 1.5% |
| Forward P/E | 29.9x | 12.1x |
| Total Debt | $45M | $93.59B |
| Cash & Equiv. | $66M | $8.51B |
GRDN vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Guardian Pharmacy S… (GRDN) | 100 | 217.7 | +117.7% |
| CVS Health Corporat… (CVS) | 100 | 138.1 | +38.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRDN vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GRDN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.04
- Rev growth 17.9%, EPS growth 144.1%, 3Y rev CAGR 16.8%
- 128.6% 10Y total return vs CVS's 3.9%
CVS is the clearest fit if your priority is defensive.
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.1x vs 29.9x)
- Beta 0.05 vs GRDN's 1.04
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 17.9% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (12.1x vs 29.9x) | |
| Quality / Margins | 3.6% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs GRDN's 1.04 | |
| Dividends | 3.1% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +42.3% vs CVS's +35.2% | |
| Efficiency (ROA) | 13.4% ROA vs CVS's 1.1%, ROIC 35.1% vs 5.0% |
GRDN vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
GRDN vs CVS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
GRDN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CVS is the larger business by revenue, generating $407.9B annually — 280.2x GRDN's $1.5B. Profitability is closely matched — net margins range from 3.6% (GRDN) to 0.7% (CVS). On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.5B | $407.9B |
| EBITDAEarnings before interest/tax | $112M | $9.4B |
| Net IncomeAfter-tax profit | $53M | $2.9B |
| Free Cash FlowCash after capex | $70M | $7.4B |
| Gross MarginGross profit ÷ Revenue | +20.2% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +1.5% |
| Net MarginNet income ÷ Revenue | +3.6% | +0.7% |
| FCF MarginFCF ÷ Revenue | +4.8% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.2% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +40.0% | +63.1% |
Valuation Metrics
CVS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 46.9x trailing earnings, GRDN trades at a 25% valuation discount to CVS's 62.5x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than GRDN's 20.6x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.3B | $111.3B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $196.4B |
| Trailing P/EPrice ÷ TTM EPS | 46.90x | 62.49x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.86x | 12.13x |
| PEG RatioP/E ÷ EPS growth rate | 2.50x | — |
| EV / EBITDAEnterprise value multiple | 20.64x | 13.10x |
| Price / SalesMarket cap ÷ Revenue | 1.60x | 0.28x |
| Price / BookPrice ÷ Book value/share | 10.62x | 1.46x |
| Price / FCFMarket cap ÷ FCF | 28.71x | 14.26x |
Profitability & Efficiency
GRDN leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
GRDN delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $4 for CVS. GRDN carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), GRDN scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +25.4% | +3.9% |
| ROA (TTM)Return on assets | +13.4% | +1.1% |
| ROICReturn on invested capital | +35.1% | +5.0% |
| ROCEReturn on capital employed | +41.5% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.21x | 1.24x |
| Net DebtTotal debt minus cash | -$21M | $85.1B |
| Cash & Equiv.Liquid assets | $66M | $8.5B |
| Total DebtShort + long-term debt | $45M | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | 101.92x | 4.19x |
Total Returns (Dividends Reinvested)
GRDN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GRDN five years ago would be worth $22,862 today (with dividends reinvested), compared to $11,843 for CVS. Over the past 12 months, GRDN leads with a +42.3% total return vs CVS's +35.2%. The 3-year compound annual growth rate (CAGR) favors GRDN at 31.7% vs CVS's 10.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +23.9% | +10.1% |
| 1-Year ReturnPast 12 months | +42.3% | +35.2% |
| 3-Year ReturnCumulative with dividends | +128.6% | +35.9% |
| 5-Year ReturnCumulative with dividends | +128.6% | +18.4% |
| 10-Year ReturnCumulative with dividends | +128.6% | +3.9% |
| CAGR (3Y)Annualised 3-year return | +31.7% | +10.8% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than GRDN's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.0% from its 52-week high vs GRDN's 88.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.04x | 0.05x |
| 52-Week HighHighest price in past year | $41.36 | $88.63 |
| 52-Week LowLowest price in past year | $19.17 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +88.4% | +98.0% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 443K | 7.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GRDN as "Buy" and CVS as "Buy". Consensus price targets imply 9.6% upside for CVS (target: $95) vs 3.9% for GRDN (target: $38). CVS is the only dividend payer here at 3.08% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $38.00 | $95.20 |
| # AnalystsCovering analysts | 3 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +3.1% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.3% | 0.0% |
GRDN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility).
GRDN vs CVS: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is GRDN or CVS a better buy right now?
For growth investors, Guardian Pharmacy Services, Inc.
(GRDN) is the stronger pick with 17. 9% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Guardian Pharmacy Services, Inc. (GRDN) offers the better valuation at 46. 9x trailing P/E (29. 9x forward), making it the more compelling value choice. Analysts rate Guardian Pharmacy Services, Inc. (GRDN) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GRDN or CVS?
On trailing P/E, Guardian Pharmacy Services, Inc.
(GRDN) is the cheapest at 46. 9x versus CVS Health Corporation at 62. 5x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GRDN or CVS?
Over the past 5 years, Guardian Pharmacy Services, Inc.
(GRDN) delivered a total return of +128. 6%, compared to +18. 4% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: GRDN returned +128. 6% versus CVS's +3. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GRDN or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Guardian Pharmacy Services, Inc. 's 1. 04β — meaning GRDN is approximately 1956% more volatile than CVS relative to the S&P 500. On balance sheet safety, Guardian Pharmacy Services, Inc. (GRDN) carries a lower debt/equity ratio of 21% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — GRDN or CVS?
By revenue growth (latest reported year), Guardian Pharmacy Services, Inc.
(GRDN) is pulling ahead at 17. 9% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Guardian Pharmacy Services, Inc. grew EPS 144. 1% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, GRDN leads at 16. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GRDN or CVS?
Guardian Pharmacy Services, Inc.
(GRDN) is the more profitable company, earning 3. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 3. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRDN leads at 6. 1% versus 2. 6% for CVS. At the gross margin level — before operating expenses — GRDN leads at 19. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GRDN or CVS more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
1x forward P/E versus 29. 9x for Guardian Pharmacy Services, Inc. — 17. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CVS: 9. 6% to $95. 20.
08Which pays a better dividend — GRDN or CVS?
In this comparison, CVS (3.
1% yield) pays a dividend. GRDN does not pay a meaningful dividend and should not be held primarily for income.
09Is GRDN or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 9%, GRDN: +128. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GRDN and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GRDN is a small-cap high-growth stock; CVS is a mid-cap income-oriented stock. CVS pays a dividend while GRDN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.